34 results about "Ischnocnema bolbodactyla" patented technology

The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

An immunogenic composition, and method of using the composition, composed of a capsule polysaccharide polymer from one or more strains Campylobacter jejuni. The composition is either used alone or is conjugated to a carrier molecule, such as CRM197. An aspect of the invention is that the immunogenic composition induces an immune response without the induction of Gulliam Barre Syndrome.

The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.

The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Camplylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

The present invention provides, e.g., sialyltransferase proteins comprising conserved sequence motifs, including α-2,3-sialyltransferase proteins from C. jejuni strains O:36 and O:19. The invention also provides methods of making sialylated products using those sialyltransferases.

The invention discloses a poultry micro-ecological preparation as well as a preparation method and application thereof. The poultry micro-ecological preparation is prepared from lactobacillus salivarius Scgz-11 bacterium powder, lactobacillus salivarius SCL87 bacterium powder and lactobacillus ingluviei SCGZ-9 bacterium powder; selected strains are strains separated from healthy chicken flocks; a plurality of times of inspection and screening of the strains prove that the strains are safe, reliable and stable. The poultry micro-ecological preparation has no pollution of infectious microbes in a production process, high viable count and long storage period, resists gastric acid and has enteric solubility and water solubility; the poultry micro-ecological preparation can be mixed with feed and water to feed and is convenient and feasible; the poultry micro-ecological preparation has the effects of efficiently preventing and controlling poultry campylobacter jejuni diseases, poultry salmonellosis or poultry colibacillosis; the poultry micro-ecological preparation also has the effects of improving the ecological balance of poultry intestinal flora, enhancing the immunologic function, promoting the growth, improving the feed utilization rate and preventing and controlling diarrhea diseases. The poultry micro-ecological preparation has very important meanings of guaranteeing food safety and human health.

Multiplex PCR primers that can amplify the cdt genes of C. jejuni, C. coli, and C. fetus in a bacterial species-specific manner were prepared. Multiplex PCR with the primers was assessed using Campylobacter bacteria, other cdt gene-positive bacteria, and representative bacteria responsible for enteric infection. As a result, the present inventors' multiplex PCR using cdtB amplification primers was proven to enable simultaneous detection of different Campylobacter bacteria with high specificity. The methods of the present invention can identify Campylobacter at the bacterial species level in a single manipulation even when domestic animals or humans are infected with different bacterial species of Campylobacter.

Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.

The invention belongs to the field of bacterial drug-resistant molecular detection, and relates to a multiple real-time fluorescent PCR method for identifying the drug-resistant mutation of macrolides and for identifying Campylobacter jejuni. The method is characterized in that an idiocratic primer, MGB probe, and combination of both are designed, not only is the specificity identification performed for the Campylobacter jejuni, but also the mutation of nucleotide of 2074th and 2075th of the 23S rRNA gene of Campylobacter jejuni and that of nucleotide of 170th and 221st of L4 flagellum gene rp1D of ribosome protein can be detected at the same time. The quick detection for drug-resistant mutation points of the various macrolides and the specificity identify for the Campylobacter jejuni are realized, which is first realized in the same reaction system, so that the identification and drug tolerance detection for the Campylobacter jejuni in clinical trials is greatly reduced, and as a result, a novel method is provided for Campylobacter jejuni drug-resistant monitoring and medicines for clinical trials infection treatment.

The invention relates to a detection method of the polymerase chain reaction of jejunum campylobacter, comprising the steps that micro-oxygen-needed separated cultivation is carried out to the jejunum campylobacter, suspicious colony is selected to be dissolved in a buffer solution specially used for dissolving the jejunum campylobacter, supernatant is taken out to be used as the template of PCR after boiling decentralization; then, a pair of specific primers are designed according to a conservative segment in a VS1 gene sequence of the jejunum campylobacter to carry out PCR reaction, the reaction product is observed by using agarose gel electrophoresis, and positive result is obtained if a 516bp strip appears. The method of the invention detects the jejunum campylobacter directly from the suspicious colony, the process of bacteria-increasing cultivation is eliminated, and the designed specific primers improve the sensitivity and the specificity of the PCR detection method, thus solving the difficulty of long detection time of the jejunum campylobacter by the conventional method, and providing a reliable and fast detection method for the detection of the jejunum campylobacter in livestock, fowl and the products thereof.

The invention relates to pediococcus pentosaceus CCFM1012 as well as a fermented food thereof and application thereof in preparation of a medicine for antagonizing campylobacter jejuni infection. Thepediococcus pentosaceus CCFM1012 provided by the invention can be used for remarkably reducing the field planting rate of campylobacter jejuni in a campylobacter jejuni infected mouse, and transcriptional activity of campylobacter jejuni virulence genes flaA, cadF, cdtB, cdtC and dnaJ; physiological damages caused by the campylobacter jejuni infection are effectively alleviated and the pediococcuspentosaceus CCFM1012 also can be used for preparing dairy products, bean products and fruit and vegetable products for preventing the campylobacter jejuni infection. The pediococcus pentosaceus CCFM1012 also can be used for preparing an additive capable of being added into feed for poultries and domestic animals and the additive is used for reducing infection and carrying of the campylobacter jejuni in the poultries and the domestic animals; therefore, the pediococcus pentosaceus CCFM1012 has a very wide application prospect.

The invention discloses Lactobacillus reuteri, which can antagonize Campylobacter jejuni and inhibit its flaA gene expression, has better acid and bile salt tolerance, can inhibit in vitro the growth of Campylobacter jejuni, and has better ability to adhere intestinal epithelial cells. Ferment supernate of Lactobacillus reuteri has the expression of flaA gene of Campylobacter jejuni down-regulated in vitro by 11.1 times when compared to a control, and the synthesis of flagella of Campylobacter jejuni can be effectively inhibited; the ferment supernate of Lactobacillus reuteri has the expression of the flaA gene of Campylobacter jejuni down-regulated in a cell model by 1.4 times when compared to a control. The Lactobacillus reuteri is applicable to the preparation and drugs for preventing and treating diseases caused by Campylobacter jejuni, for the preparation of fermented milk and the like, and has a promising application prospect.

An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes.The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.

The invention relates to a method for constructing an expression system of exogenous genes in a campylobacter jejuni. Under the condition of anaerobic environment and temperature controlled at 37 DEG C, the method comprises the steps of preparing promoters, constructing the shuttle plasmids, and establishing a bioluminescent transgene model of the campylobacter jejuni. By using electrotransformation to introduce the campylobacter jejuni ATCC33291 and ATCC35921 which are expressed under the selection pressure of kanamycin antibiotics, the method can observe bioluminescence without adding any substrate, visually expresses bioinformation, and has a wide research prospect.

The present invention provides a heat-stable and protease-resistant antibacterial activity in excretory-secretory products (ESP) of Trichuris suis. The antibacterial activity is not more than 10,000 MW; is resistant to boiling, trypsin, and pronase E; has a bactericidal mode of action; and is effective against Gram positive and Gram negative bacteria, including Escherichia coli, Campylobacter jejuni, Campylobacter coli, and Staphylococcus aureus. The antibacterial activity is useful in applications for killing or inhibiting the growth of microorganisms, in particular bacteria.

The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing and anti-C. jejuni immune response.

The invention discloses lactobacillus plantarum. The Lactobacillus plantarum can antagonize campylobacter jejuni and inhibit expression of a flaA gene of the campylobacter jejuni, has the good acid resistance and bile salt resistance, can inhibit growth of the campylobacter jejuni in vitro and has the good adhesive capacity on the intestinal epithelial cells. A fermentation supernatant of the lactobacillus plantarum enables the expression amount of the flaA gene of the campylobacter jejuni to be reduced by 8.2 times compared with a control group in vitro, and synthesis of campylobacter jejuni flagella is effectively inhibited; the lactobacillus plantarum enables the expression amount of the flaA gene of the campylobacter jejuni to be reduced by 1.7 times compared with a control group in a cell model. The lactobacillus plantarum can be used for preparing medicine for preventing and treating diseases caused by the campylobacter jejuni and participate in preparing fermentation milk products and the like and has the wide application prospect.

The invention provides a diarrhoea-resisting premix agent capable of reducing campylobacter jejuni of piggies as well as a preparation method and application of the diarrhoea-resisting premix agent, and relates to the field of feed additives. The diarrhoea-resisting premix agent comprises the following raw materials in parts by weight: lactobacilli, galacto-mannan-oligosaccharides, berberine, calcium phthalate, forall porcine pepton and montmorillonite, and the diarrhoea-resisting premix agent can reduce the campylobacter jejuni of the piggies, the disease resistance of the piggies is improved, and health and product quality of the piggies can be guaranteed. The preparation method of the diarrhoea-resisting premix agent capable of reducing campylobacter jejuni of piggies comprises the following steps of firstly, mixing the berberine with the galacto-mannan-oligosaccharides, then adding the lactobacilli and the forall porcine pepton, then performing mixing, then adding the calcium phthalate and the montmorillonite, and then performing mixing. The method is simple, the diarrhoea-resisting premix agent capable of reducing campylobacter jejuni of piggies is applied, and added to feedsor drinking water of the piggies, so that condition that the piggies suffer from campylobacter jejuni is reduced, and the disease resistance of the piggies is improved.

The invention discloses an identification method for campylobacter jejuni infection-associated chicken microRNA. The identification method comprises the following steps of: a first step of collecting chicken meconium, and detecting a positive rate of campylobacter jejuni; a second step of collecting cecum content for counting campylobacter jejuni and cecum tissue samples for RNA extraction; a third step of extracting total RNA of samples, detecting quality, and mixing in a tank; a fourth step of constructing a sequencing sample library; a fifth step of carrying out Solexa sequencing; a sixth step of carrying out subsequent analysis; a seventh step of predicating a target gene of the microRNA; an eighth step of obtaining campylobacter jejuni cfu infection-assocaited chicken microRNAs according to the microRNA and the target gene information thereof. The identification method disclosed by the invention regulates the target gene of the microRNA to indirectly participate in a plurality of immune-associated signal channels, so that important regulation effect is achieved in campylobacter jejuni infection; the microRNAs can be important candidate microRNAs in anti-campylobacter jejuni infection breeding, and foundation is laid up for deeply researching an acting mechanism of the microRNAs in campylobacter jejuni in future, so that theoretical basis and scientific basis are provided for molecular disease-resistant breeding of chicken.

The invention belongs to the biotechnical field, relating to a method for detecting drug-resistant related gene mutation of campylobacter jejuni macrolide drugs. The method makes use of a realtime fluorescence quantitative PCR TaqMan probe technology to design a specific primer and a probe according to a nucleic acid sequence of a V zone inside a campylobacter jejuni macrolide drug-resistant mutation zone 23S rDNA; moreover, through optimizing a TaqMan realtime fluorescence quantitative PCR reaction system and conditions, related drug-resistant mutational sites of target genes are accurately detected. The method can realize quick, accurate and simultaneous detection of two main drug-resistant mutational sites of campylobacter jejuni macrolide type, and has better specificity and higher sensitivity than a related molecular biology detection method reported at present; moreover, the method has simple operation, high accuracy and quick speed compared with the prior sequencing and drug sensitive experimental method. The method provides an effective technical means for molecular epidemiological monitoring of macrolide campylobacter jejuni resistance.

The invention relates to a detection kit for Campylobacter jejuni in pork. The detection kit comprises a culture medium and a detection solution, wherein the culture medium is broth. The detection solution is composed of 3-5 mu l of 10 PCR (polymerase chain reaction) buffer solution, 0.2-0.4 mu l of Taq DNA (deoxyribonucleic acid) polymerase, 3-5 mu l of dNTP (deoxyribonucleotide triphosphate), 0.1-0.6 mu l of 100bp DNA Ladder Marker, 1-2 mu l of PCR primer, 5-10 ml of Tris.cl, 1-2.2mg of sodium chloride, 1-2.2mg of magnesium chloride, 0.2-0.5mg of disodium hydrogen phosphate dodecahydrate and 3-5mg of enrichment broth. The detection kit is an improvement on the basis of the conventional PCR technology, and can be used for qualitative detection of Campylobacter jejuni. By integrating the advantages of PCR, DHPLC (denaturing high performance liquid chromatography) and other techniques, the detection kit has the advantages of high specificity of detection results and high sensitivity, and ensures the effective detection of Campylobacter jejuni in food.

Methods and compositions for reducing the incidence of C. jejuni bacteria infections in poultry and in humans and other animals are formulated to include C. jejuni antigens, and particularly CadF, FlpA and FlaA. The antigens may be provided in the form of polypeptides or by hosts that produce the antigens. Fibronectin binding proteins of C. jejuni may also be used to deliver substances of interest to humans and other animals.

The invention belongs to the field of bacterial drug-resistant molecular detection, and relates to a multiple real-time fluorescent PCR method for identifying the drug-resistant mutation of macrolides and for identifying Campylobacter jejuni. The method is characterized in that an idiocratic primer, MGB probe, and combination of both are designed, not only is the specificity identification performed for the Campylobacter jejuni, but also the mutation of nucleotide of 2074th and 2075th of the 23S rRNA gene of Campylobacter jejuni and that of nucleotide of 170th and 221st of L4 flagellum gene rp1D of ribosome protein can be detected at the same time. The quick detection for drug-resistant mutation points of the various macrolides and the specificity identify for the Campylobacter jejuni are realized, which is first realized in the same reaction system, so that the identification and drug tolerance detection for the Campylobacter jejuni in clinical trials is greatly reduced, and as a result, a novel method is provided for Campylobacter jejuni drug-resistant monitoring and medicines for clinical trials infection treatment.

The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against C. jejuni in a subject comprising one or more MeOPN-6-Gal monosaccharides, one or more MeOPN-4-Gal monosaccharides, and / or one or more MeOPN-2-Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs, and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and / or compositions comprising the immunogenic synthetic constructs, to the subject. Methods of treating, preventing, or ameliorating a C. jejuni bacterial infection in a subject comprising administering to the subject one or more doses of immunoglobulins directed to one or more of the MeOPN moieties are also contemplated.

The invention discloses lactobacillus plantarum. The Lactobacillus plantarum can antagonize campylobacter jejuni and inhibit expression of a flaA gene of the campylobacter jejuni, has the good acid resistance and bile salt resistance, can inhibit growth of the campylobacter jejuni in vitro and has the good adhesive capacity on the intestinal epithelial cells. A fermentation supernatant of the lactobacillus plantarum enables the expression amount of the flaA gene of the campylobacter jejuni to be reduced by 8.2 times compared with a control group in vitro, and synthesis of campylobacter jejuni flagella is effectively inhibited; the lactobacillus plantarum enables the expression amount of the flaA gene of the campylobacter jejuni to be reduced by 1.7 times compared with a control group in a cell model. The lactobacillus plantarum can be used for preparing medicine for preventing and treating diseases caused by the campylobacter jejuni and participate in preparing fermentation milk products and the like and has the wide application prospect.